WORK Medical adds new independent director
WORK Medical Technology Group LTD reports a change in its board of directors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
WORK Medical Technology Group LTD reports a change in its board of directors. On March 23, 2026, independent director Xiaoyang Li resigned from the Board, the Audit, Compensation, and Nominating and Corporate Governance Committees, and as chairperson of the Compensation Committee, citing personal reasons.
To fill this vacancy, the Board appointed Dr. Qisheng Lin as an independent director, a member of all three committees, and chairperson of the Compensation Committee, effective the same day. Dr. Lin is a nephrology specialist and academic with roles at Renji Hospital and prior research experience at the Icahn School of Medicine at Mount Sinai. The Board determined he meets the Nasdaq “independent director” standard. This report is incorporated by reference into the Company’s Form F-3 registration statement (File No. 333-289943).
Key Figures
Effective date of resignation and appointment: March 23, 2026
Form F-3 file number: 333-289943
Company phone number: +86-571-82613568
+1 more
4 metrics
Effective date of resignation and appointment
March 23, 2026
Board and committee changes became effective on this date
Form F-3 file number
333-289943
Registration statement into which this report is incorporated
Company phone number
+86-571-82613568
Contact for WORK Medical Technology Group’s principal executive office
Report signature date
April 15, 2026
Date the report was signed by the Chief Executive Officer
Key Terms
independent director, Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, +2 more
6 terms
independent director financial
"Mr. Xiaoyang Li, an independent director of WORK Medical Technology Group LTD"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Audit Committee financial
"resigned from the board of directors and as a member of the Audit Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Compensation Committee financial
"and as the chairperson of the Compensation Committee of the Board"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
Nominating and Corporate Governance Committee financial
"a member of each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Nasdaq Listing Rule 5605(a)(2) financial
"The Board has determined that Dr. Lin is an “independent director” as defined under Nasdaq Listing Rule 5605(a)(2)."
Nasdaq Listing Rule 5605(a)(2) sets the criteria Nasdaq uses to decide whether a company’s board members are independent, listing examples of relationships or ties that would disqualify a director from being considered independent. Investors care because a board with genuinely independent directors acts like an impartial referee overseeing management decisions, reducing conflicts of interest and improving the chance that shareholder interests are protected and corporate decisions are scrutinized effectively.
Form F-3 regulatory
"incorporated by reference into the registration statement of the Company on Form F-3"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did WORK Medical Technology Group (WOK) disclose in this 6-K?
WORK Medical Technology Group reported that independent director Xiaoyang Li resigned from the Board and three key committees on March 23, 2026. His roles included chairing the Compensation Committee, creating a vacancy the company needed to promptly fill with another independent director.
Who was appointed to replace Xiaoyang Li on the WORK Medical Technology Group (WOK) board?
The company appointed Dr. Qisheng Lin as an independent director on March 23, 2026. He also joined the Audit, Compensation, and Nominating and Corporate Governance Committees and became chairperson of the Compensation Committee, filling the responsibilities previously held by Xiaoyang Li.
Why did Xiaoyang Li resign from WORK Medical Technology Group (WOK)?
Xiaoyang Li resigned from the Board and its committees on March 23, 2026, due to personal reasons. The filing does not describe any disagreement with the company, focusing instead on the prompt appointment of a new independent director to maintain board and committee composition.
What qualifications does Dr. Qisheng Lin bring to the WORK Medical Technology Group (WOK) board?
Dr. Qisheng Lin has extensive medical and academic experience, including serving as an Associate Professor in Nephrology at Renji Hospital since January 2025. He previously held research roles at the Icahn School of Medicine at Mount Sinai and completed a residency in Internal Medicine at Renji Hospital.
Is Dr. Qisheng Lin considered independent under Nasdaq rules for WORK Medical Technology Group (WOK)?
Yes, the Board determined that Dr. Qisheng Lin is an independent director under Nasdaq Listing Rule 5605(a)(2). The filing also notes he has no family relationships with company directors or executives and no related-party transactions requiring disclosure under Regulation S-K Item 404(a).
How does this 6-K relate to WORK Medical Technology Group’s (WOK) Form F-3?
The report is deemed incorporated by reference into WORK Medical Technology Group’s Form F-3 registration statement, File No. 333-289943. This means the director and committee changes described become part of the disclosure package available to investors under that registration statement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates